Everence Capital Management Inc buys $1,074,305 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Everence Capital Management Inc scooped up 18,360 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 23,900 shares of Abbott Laboratories which is valued at $1,074,305.Abbott Laboratories makes up approximately 0.32% of Everence Capital Management Inc’s portfolio.

Other Hedge Funds, Including , Private Harbour Investment Management Counsel boosted its stake in ABT in the latest quarter, The investment management firm added 4,525 additional shares and now holds a total of 49,462 shares of Abbott Laboratories which is valued at $2,223,317. Abbott Laboratories makes up approx 1.79% of Private Harbour Investment Management Counsel’s portfolio.Harvey Investment Co reduced its stake in ABT by selling 200 shares or 0.08% in the most recent quarter. The Hedge Fund company now holds 244,943 shares of ABT which is valued at $10,961,199. Abbott Laboratories makes up approx 2.31% of Harvey Investment Co’s portfolio.Capital Advantage boosted its stake in ABT in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 5,071 shares of Abbott Laboratories which is valued at $213,438. Abbott Laboratories makes up approx 0.07% of Capital Advantage’s portfolio.Ct Financial Advisors reduced its stake in ABT by selling 729 shares or 17.08% in the most recent quarter. The Hedge Fund company now holds 3,540 shares of ABT which is valued at $148,291. Abbott Laboratories makes up approx 0.09% of Ct Financial Advisors’s portfolio.

Abbott Laboratories closed down -0.14 points or -0.31% at $44.81 with 65,83,457 shares getting traded on Thursday. Post opening the session at $45.06, the shares hit an intraday low of $44.78 and an intraday high of $45.09 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.